Longitudinal Outcomes of Dolutegravir-Based Antiretroviral Therapy in a Large Nigerian Programmatic HIV-1 Cohort, 2017–2019
Open Access
- 28 August 2026
- journal article
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (9)
Abstract
In a retrospective Nigerian cohort of 33 982 people with HIV-1 initiating or switching to tenofovir, lamivudine, and dolutegravir, virological suppression reached 80%–82% among participants with available viral load data and 63%–65% by intention-to-treat analysis. Suppression was higher among switchers, while age and gender predicted suppression.Keywords
Funding Information
- Cipher
- Zukunftskolleg, Universität Konstanz
- International AIDS Society
- International Health
- Wellcome Trust (WT108082AIA)
- Hong Kong Jockey Club Global Health Institute
- Hong Kong Special Administrative Region
This publication has 19 references indexed in Scilit:
- Prevalence and factors associated with viral non‐suppression in people living with HIV receiving antiretroviral therapy in sub‐Saharan Africa: A systematic review and meta‐analysisReviews in Medical Virology, 2024
- Estimation of HIV prevalence and burden in Nigeria: a Bayesian predictive modelling studyeClinicalMedicine, 2023
- Two-Year Outcomes of Treatment-Experienced Adults After Programmatic Transitioning to Dolutegravir: Longitudinal Data From the VICONEL Human Immunodeficiency Virus Cohort in LesothoClinical Infectious Diseases, 2023
- Viral suppression and HIV-1 drug resistance 1 year after pragmatic transitioning to dolutegravir first-line therapy in Malawi: a prospective cohort studyThe Lancet HIV, 2022
- Life expectancy of people with HIV on long-term antiretroviral therapy in Europe and North America: a cohort studyThe Lancet Healthy Longevity, 2022
- Reduced efficacy of HIV-1 integrase inhibitors in patients with drug resistance mutations in reverse transcriptaseNature Communications, 2020
- Determining virological suppression and resuppression by point-of-care viral load testing in a HIV care setting in sub-Saharan AfricaeClinicalMedicine, 2020
- HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysisThe Lancet Infectious Diseases, 2018
- Improved life expectancy of people living with HIV: who is left behind?The Lancet HIV, 2017
- Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort studyThe Lancet Infectious Diseases, 2016